Ad Header

PharmaLive

Slogan

The Pulse of the Pharmaceutical Industry

  • Filter By Category

  • Filter By Author

Sanofi Whistleblower Alleges Company Attorneys Destroyed Documents

As a whistleblower lawsuit against Paris-based Sanofi (SNY) steams ahead, ex-paralegal Diane Ponte alleges that Sanofi lawyers destroyed documents rather than provide them in other legal cases.   Ponte has accused Sanofi, among other things, of shifting $34 million in kickbacks and “incentive payments” to doctors and pharmacies to influence them to prescribe its diabetes […]

Read More »

Novartis AG Fesses Up to Valeant-Like Pharmacy Scheme in $390 Million Settlement

BASEL, Switzerland – Novartis AG (NVS) will pay $390 million to settle a civil lawsuit related to the kickback payments to specialty pharmacy companies that distributed the drugs Exjade and Myfortic, Novartis announced Friday. The settlement, which is between Novartis Pharmaceutical Corporation (NVS), a U.S. subsidiary of Novartis AG, will be paid to both the […]

Read More »

AstraZeneca Sells Crohn’s Drug Rights to Perrigo for $380 Million

AstraZeneca enters into agreement with Perrigo for rights to Entocort in the US Divestment  further sharpens focus on three main therapy areas Agreement follows ex-US divestment of Entocort in July 2015   23 November 2015 AstraZeneca today announced that it has entered into an agreement with Perrigo Company plc for the divestment of US rights […]

Read More »

Pfizer Marries Allergan in $160 Billion Deal With Pfizer’s Read to Stay as CEO and Chairman

After three weeks of speculation New York-based Pfizer Inc. (PFE) announced today that it was merging with Dublin, Ireland-based Allergan plc (AGN). Board members for both companies unanimously voted Sunday to approve the deal, which will have a total enterprise value of about $160 billion.   The deal will be a stock transaction of about […]

Read More »

Roche buoyed by early data on atezolizumab in advanced melanoma

Swiss drugmaker Roche released on Monday what it called encouraging early data on cancer drug atezolizumab in combination therapy for treating a form of advanced melanoma.   A phase Ib study of atezolizumab (MPDL3280A), used in combination with the BRAF inhibitor Zelboraf for previously untreated BRAFV600 mutation-positive inoperable or metastatic melanoma, showed adverse events were […]

Read More »

Movember 2015 brings you the Sexy Men of Technology Calendar

More than just humor–it’s humor with a message   Columbus, Ohio – GSW, an industry leader in healthcare advertising and an inVentiv Health company, and LiveTiles, a global technology company headquartered in Times Square, NYC, have partnered to unveil the Sexy Men of Technology Calendar for Movember 2015, a public awareness campaign from the Movember […]

Read More »

Novartis gets FDA approval for skin cancer drug combination

Novartis AG said on Friday it received the U.S. Food and Drug Administration’s regular approval for a drug combination to treat an aggressive form of skin cancer. The FDA approved Tafinlar and Mekinist for treatment of metastatic melanoma based on two years overall survival in patients, the company said. The combination was initially approved based […]

Read More »

NovoCure’s cancer therapy effective in late-stage study

NovoCure Ltd said its lead cancer therapy improved survival rate in brain cancer patients in combination with Avastin in a late-stage study, sending its shares up 23 percent in extended trading. NovoCure’s therapy, Optune, which was evaluated in combination with Roche Holding AG’s cancer drug, reduced the risk of death by 39 percent in patients, […]

Read More »

Celldex vaccine improves long-term brain cancer survival in study

New data from a midstage trial show that Celldex Therapeutics Inc’s experimental brain cancer vaccine, combined with standard therapy, continues to improve chances of survival for patients with recurrent cancer. The updated results sent shares of Celldex up $1.74, or 12 percent, to $16.23 on the Nasdaq. The therapy, designed to enlist the body’s immune […]

Read More »

Bumper haul of expensive new drugs heads to U.S. and Europe

Drug companies have brought a host of expensive new medicines to market in the United States and Europe this year, figures show, another bumper haul for an industry often accused of over-charging. Drug prices are set to be a major issue in the run-up to the U.S. presidential election next year, with Democratic candidate Hillary […]

Read More »

Ad Right Top

MedAdNews

Extensive pharmaceutical business and marketing intelligence. For back issues, please contact MDAD@kmpsgroup.com.

December 2018 Focus: Healthcare Agency Roundtable, Mobile Marketing, and more!

Subscribe

Ad Right Bottom